A look at the interim results from the BMS CheckMate-214 trial in renal cell carcinoma
A post mortem analysis of the Bavarian Nordic PROSTVAC cancer vaccine trial failure in CRPC
An early look at a new IO combination that may help overcome resistance to checkpoint therapy
A look at the last day of ESMO17 with key data on cancer vaccines, checkpoint and targeted therapies to explore
A roundup of the key trials and targets presented on Sunday at #ESMO17
A look at mostly lung cancer highlights from the first 2 days at #ESMO17
Rucaparib likely joins the early maintenance PARP club in ovarian cancer with their ARIEL3 data at #ESMO17
A look at some of the small biotechs and what they're developing on IO front that looks intriguing at #ESMO17
8 key ImmunoOnc studies being presented at #ESMO17 this month
A look at the changing HCC market and how pipeline agents may (or may not) impact the landscape...
An eclectic selection of important abstracts involving targeted therapies to watch out for at #ESMO17
Top 5 IO oral abstracts to watch out for in Madrid
